Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor and Collaborators
Celgene Corporation
Multiple Myeloma Research Consortium
Contact
Bond V. Vo, PharmD, RPh
+ 1 (908) 673-9232
[email protected]
Continue Reading
Investigator
Ye Hua, MD, MPH
Celgene Corporation
ClinicalTrials.gov Identifier
NCT01497093